Pathogenesis and treatment of autoimmune rheumatic diseases

Purpose of review Autoimmune diseases are of unknown origin, and they represent significant causes of morbidity and mortality. Here, we review new developments in the understanding of their pathogenesis that have led to development of well tolerated and effective treatments. Recent findings In addition to the long-recognized genetic impact of the HLA locus, interferon regulatory factors, PTPN22, STAT4, and NOX have been implicated in pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Smoking, ultraviolet light, diet, and microbiota exert strong environmental influence on development of RA and SLE. Metabolism has been recognized as a critical integrator of genetic and environmental factors, and it controls immune cell differentiation both under physiological and pathological conditions. Summary With the advent of high-throughput genetic, proteomic, and metabolomic technologies, the field of medicine has been shifting towards systems-based and personalized approaches to diagnose and treat common conditions, including rheumatic diseases. Regulatory checkpoints of metabolism and signal transduction, such as glucose utilization, mitochondrial electron transport, JAK, mTOR, and AMPK pathway activation, and production of pro-inflammatory cytokines IL-1, IL-6, and IL-17 have presented new targets for therapeutic intervention. This review amalgamates recent discoveries in genetics and metabolomics with immunological pathways of pathogenesis in rheumatic diseases.

• Publication year

  2019

• Venue

  Current Opinion in Rheumatology

• Publication date

  2019-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/BOR.0000000000000594PMID 30920455PMCID PMC6447054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epigenome-wide association study of peripheral blood mononuclear cells in systemic lupus erythematosus: Identifying DNA methylation signatures associated with interferon-related genes based on ethnicity and SLEDAI.

  2019cited by this paper
• Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

  2018cited by this paper
• Proliferation of rheumatoid arthritis fibroblast-like synoviocytes is enhanced by IL-17-mediated autophagy through STAT3 activation

  2018cited by this paper
• Epigenetic Regulation of Autophagy: A Path to the Control of Autoimmunity

  2018cited by this paper
• Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.

  2018cited by this paper
• Biologics for treating axial spondyloarthritis

  2018cited by this paper
• ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer

  2018cited by this paper
• Integration of genetics and miRNA–target gene network identified disease biology implicated in tissue specificity

  2018cited by this paper
• Monogenic Lupus: A Developing Paradigm of Disease

  2018cited by this paper
• New insights into the genetics and epigenetics of systemic sclerosis

  2018cited by this paper
• “Immune TOR-opathies,” a Novel Disease Entity in Clinical Immunology

  2018cited by this paper
• Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index

  2018cited by this paper
• Autoimmune manifestations of infections

  2018cited by this paper
• Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

  2018cited by this paper
• Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis

  2018cited by this paper
• Rheumatoid arthritis and citrullination

  2018cited by this paper
• Negative selection, epitope mimicry and autoimmunity.

  2017cited by this paper
• Histone demethylase JMJD3 regulates CD11a expression through changes in histone H3K27 tri-methylation levels in CD4+ T cells of patients with systemic lupus erythematosus

  2017cited by this paper
• The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials

  2017cited by this paper
• Immune modulation of some autoimmune diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity

  2017cited by this paper
• Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.

  2017cited by this paper
• IL-17-mediated mitochondrial dysfunction impairs apoptosis in rheumatoid arthritis synovial fibroblasts through activation of autophagy

  2017cited by this paper
• Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon–Induced Up‐Regulation of Interferon Regulatory Factor 1

  2017cited by this paper
• From microbiome to infectome in autoimmunity

  2017cited by this paper
• Trial of Tocilizumab in Giant‐Cell Arteritis

  2017cited by this paper
• Review: Metabolic Control of Immune System Activation in Rheumatic Diseases

  2017cited by this paper
• Association of MicroRNA‐618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis

  2017cited by this paper
• The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned.

  2016cited by this paper
• Targeting miR-155 to Treat Experimental Scleroderma

  2016cited by this paper
• MicroRNA therapeutics: Discovering novel targets and developing specific therapy

  2016cited by this paper
• Systemic lupus erythematosus in 2015: Cellular and metabolic requirements of effector T cells

  2016cited by this paper
• Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases

  2016cited by this paper
• Inhibition of MicroRNA‐21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis

  2016cited by this paper
• Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway

  2016cited by this paper
• The Interplay Between Monocytes/Macrophages and CD4+ T Cell Subsets in Rheumatoid Arthritis

  2015cited by this paper
• Defective removal of ribonucleotides from DNA promotes systemic autoimmunity.

  2015cited by this paper
• Human parvovirus B19 and autoimmune diseases. Review of the literature and pathophysiological hypotheses.

  2015cited by this paper
• Human Disease Phenotypes Associated With Mutations in TREX1

  2015cited by this paper
• Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin

  2015cited by this paper
• Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.

  2015cited by this paper
• Macrophage defense mechanisms against intracellular bacteria

  2015cited by this paper
• Immunometabolism: Cellular Metabolism Turns Immune Regulator*

  2015cited by this paper
• Systemic Lupus Erythematosus – A Disease with A Dysregulated Type I Interferon System

  2015cited by this paper
• Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

  2015cited by this paper
• Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1

  2015cited by this paper
• mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

  2015cited by this paper
• Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.

  2015cited by this paper
• The activation status of human macrophages presenting antigen determines the efficiency of Th17 responses.

  2015cited by this paper
• Early-stage lupus nephritis treated with N-acetylcysteine: A report of two cases.

  2015cited by this paper
• The evolution of drug discovery in systemic lupus erythematosus

  2015cited by this paper
• Mechanisms of Tumor Necrosis Factor α Antagonist–Induced Lupus in a Murine Model

  2015cited by this paper
• Glucose, glycolysis and lymphocyte responses.

  2015cited by this paper
• Mycobacteria and autoimmunity

  2015cited by this paper
• SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction.

  2015cited by this paper
• Flexibility for specificity

  2015cited by this paper
• Metabolic control of the epigenome in systemic Lupus erythematosus

  2014cited by this paper
• B cells: depletion or functional modulation in rheumatic diseases

  2014cited by this paper
• The multifactorial role of neutrophils in rheumatoid arthritis

  2014cited by this paper
• Potential Role of Bacterial Infection in Autoimmune Diseases: A New Aspect of Molecular Mimicry

  2014cited by this paper
• Growing knowledge of the mTOR signaling network.

  2014cited by this paper
• Role of viruses and bacteria-virus interactions in autoimmunity.

  2014cited by this paper
• SAMHD1 prevents autoimmunity by maintaining genome stability

  2014cited by this paper
• Th1/Th2 Paradigm Extended: Macrophage Polarization as an Unappreciated Pathogen-Driven Escape Mechanism?

  2014cited by this paper
• Structural Changes and Antibody Enrichment in the Lungs Are Early Features of Anti–Citrullinated Protein Antibody–Positive Rheumatoid Arthritis

  2014cited by this paper
• Interleukin-10 attenuation of collagen-induced arthritis is associated with suppression of interleukin-17 and retinoid-related orphan receptor γt production in macrophages and repression of classically activated macrophages

  2014cited by this paper
• Toll‐like Receptor 7–Stimulated Tumor Necrosis Factor α Causes Bone Marrow Damage in Systemic Lupus Erythematosus

  2014cited by this paper
• Cellular redox, epigenetics and diseases.

  2013cited by this paper
• Future prospects in biologic therapy for systemic lupus erythematosus

  2013cited by this paper
• Biologics-induced autoimmune diseases

  2013cited by this paper
• Succinate is an inflammatory signal that induces IL-1β through HIF-1α

  2013cited by this paper
• Oxidative stress in the pathology and treatment of systemic lupus erythematosus

  2013cited by this paper
• Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

  2013cited by this paper
• Neutrophils in innate and adaptive immunity

  2013cited by this paper
• Autoimmunity and infection in Sjögren's syndrome

  2013cited by this paper
• American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.

  2013cited by this paper
• Plasmacytoid dendritic cells: key players in viral infections and autoimmune diseases.

  2013cited by this paper
• Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus

  2013cited by this paper
• Pathogenesis and spectrum of autoimmunity.

  2012cited by this paper
• Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis

  2012cited by this paper
• N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

  2012cited by this paper
• Criteria for environmentally associated autoimmune diseases.

  2012cited by this paper
• Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.

  2012cited by this paper
• Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

  2011cited by this paper
• Th17 Response and Inflammatory Autoimmune Diseases

  2011cited by this paper
• Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation.

  2011cited by this paper
• Autophagy in immunity and inflammation

  2011cited by this paper
• Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

  2011cited by this paper
• Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus

  2011cited by this paper
• Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

  2011cited by this paper
• From a neutrophilic synovial tissue infiltrate to a challenging case of rheumatoid arthritis.

  2010cited by this paper
• Overexpression of the growth arrest and DNA damage-induced 45alpha gene contributes to autoimmunity by promoting DNA demethylation in lupus T cells.

  2010cited by this paper
• Epigenetic mechanisms in lupus

  2010cited by this paper
• B cells as therapeutic targets in SLE

  2010cited by this paper
• Autoimmune diseases induced by biological agents: a double-edged sword?

  2010cited by this paper
• Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients.

  2010cited by this paper
• Induction of Systemic Lupus Erythematosus with Tumor Necrosis Factor Blockers

  2010cited by this paper
• Autoinflammatory conditions: when to suspect? How to treat?

  2010cited by this paper
• Recent advances in the genetics of autoimmune disease.

  2009cited by this paper
• T-cell and B-cell signaling biomarkers and treatment targets in lupus

  2009cited by this paper
• Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome

  2009cited by this paper

• The causal relationship between cathepsins and ankylosing spondylitis: a two-sample Mendelian randomization study

  2026cites this paper
• Expression of miR-146a in Th17 cells from rheumatoid arthritis patients and its correlation with inflammatory cytokines.

  2025cites this paper
• Crosstalk between N6-methyladenosine modification and ncRNAs in rheumatic diseases: therapeutic and diagnostic implications

  2025cites this paper
• Electrocardiographic abnormalities and Cardiovascular outcomes in systemic autoimmune rheumatic diseases: A scoping review protocol

  2025cites this paper
• Therapeutic plasma exchange in autoimmune diseases: a retrospective study in a tertiary pediatric hospital in Mexico

  2025cites this paper
• Mikrobiom, Ernährung und Rheuma

  2025cites this paper
• From immunosuppression to immune reprogramming: is triptolide a potential “immune reset” agent in autoimmune diseases?

  2025cites this paper
• The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds.

  2024cites this paper
• Association between a single‐nucleotide polymorphism of the angiotensin‐converting enzyme gene and susceptibility to systemic lupus erythematosus in the Hainanese population of China

  2024cites this paper
• Comparative profiling of serum biomarkers and ATR-FTIR spectroscopy for differential diagnosis of patients with rheumatoid and psoriatic arthritis - a pilot study.

  2024cites this paper
• Efficacy of substances containing 3 types of active ingredients-saponins, flavones, and alkaloids in regulation of cytokines in autoimmune diseases a systematic review and Meta-analysis based on animal studies.

  2024cites this paper
• Rheumatic diseases and metabolism: where centre and periphery meet

  2024cites this paper
• Dietary tryptophan and genetic susceptibility expand gut microbiota that promote systemic autoimmune activation

  2024cites this paper
• Infectious agents in the pathogenesis of autoimmune rheumatic diseases.

  2024cites this paper
• From Suspected COVID-19 to Anti-synthetase Syndrome: A Diagnostic Challenge in the Pandemic Era

  2024cites this paper
• Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review.

  2024cites this paper
• Systemic Lupus Erythematosus and Cytokine Storm.

  2024cites this paper
• Targeted saliva metabolomics in Sjögren's syndrome

  2024cites this paper
• Signaling pathways in rheumatoid arthritis: implications for targeted therapy

  2023cites this paper
• Gastrointestinal endoscopic findings of autoimmune and autoinflammatory diseases in pediatric rheumatology patients

  2023cites this paper
• Genetic Evidence Supporting Causal Roles of mTOR-Dependent Proteins in Rheumatic Fever: A Two-Sample Randomized Mendelian Study

  2023cites this paper
• The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus

  2023cites this paper
• The effect of JuanBiQiangGu granules in combination with methotrexate on joint inflammation in rheumatoid arthritis: a randomized controlled trial

  2023cites this paper
• Anti‐inflammatory effect and mechanism of catalpol in various inflammatory diseases

  2023cites this paper
• Involvement of trained immunity during autoimmune responses.

  2022cites this paper
• A Systematic Review of Nutritional Interventions on Key Cytokine Pathways in Rheumatoid Arthritis and Its Implications for Comorbid Depression: Is a More Comprehensive Approach Required?

  2022cites this paper
• Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis

  2021cites this paper
• Deconvoluting the heterogeneity of SLE: The contribution of ancestry.

  2021cites this paper
• The molecular structure and biological functions of RNA methylation, with special emphasis on the roles of RNA methylation in autoimmune diseases

  2021cites this paper
• The role of NLRP3 inflammasome in the pathogenesis of rheumatic disease

  2021cites this paper
• Relationship between amniotic fluid metabolic profile with fetal gender, maternal age, and gestational week

  2021cites this paper
• Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies

  2021cites this paper
• A patent review of mTOR inhibitors for cancer therapy (2011–2020)

  2021cites this paper
• The Immunomodulatory and Anti-Inflammatory Effect of Curcumin on Immune Cell Populations, Cytokines, and In Vivo Models of Rheumatoid Arthritis

  2021influential citation
• EFFECTS OF PHYSICAL ACTIVITY ON VASCULAR FUNCTION IN AUTOIMMUNE RHEUMATIC DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS.

  2021cites this paper
• Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma

  2021cites this paper
• Relationship Between Amniotic Fluid Metabolic Pro�le With Fetal Gender, Maternal Age, and Gestational Age

  2021cites this paper
• Metabolic determinants of lupus pathogenesis

  2020cites this paper
• Regulation of Metabolic Processes by Hydrogen Peroxide Generated by NADPH Oxidases

  2020cites this paper
• Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire

  2020cites this paper
• The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis

  2020cites this paper
• Rosmarinic acid protects mice from Concanavalin A-induced hepatic injury through AMPK signaling.

  2020cites this paper
• Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development

  2020cites this paper
• Systemic Lupus Erythematosus and Cytokine Storm

  2019cites this paper
• Metabolic control of T cells in autoimmunity.

  2019cites this paper
• Impact of infections in autoimmune rheumatic diseases and pregnancy.

  2019cites this paper
• Targeted saliva metabolomics in Sj € ogren ’ s syndrome

  year unknowncites this paper